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To elucidate the pathomechanism leading to obstructive vascular disease in patients with elastin deficiency, we
compared both elastogenesis and proliferation rate of cultured aortic smooth-muscle cells (SMCs) and skin fibro-
blasts from five healthy control subjects, four patients with isolated supravalvular aortic stenosis (SVAS), and five
patients with Williams-Beuren syndrome (WBS). Mutations were determined in each patient with SVAS and in each
patient with WBS. Three mutations found in patients with SVAS were shown to result in null alleles. RNA blot
hybridization, immunostaining, and metabolic labeling experiments demonstrated that SVAS cells and WBS cells
have reduced elastin mRNA levels and that they consequently deposit low amounts of insoluble elastin. Although
SVAS cells laid down ∼50% of the elastin made by normal cells, WBS cells deposited only 15% of the elastin made
by normal cells. The observed difference in elastin-gene expression was not caused by a difference in the stability
of elastin mRNA in SVAS cells compared with WBS cells, but it did indicate that gene-interaction effects may
contribute to the complex phenotype observed in patients with WBS. Abnormally low levels of elastin deposition
in SVAS cells and in WBS cells were found to coincide with an increase in proliferation rate, which could be reversed
by addition of exogenous insoluble elastin. We conclude that insoluble elastin is an important regulator of cellular
proliferation. Thus, the reduced net deposition of insoluble elastin in arterial walls of patients with either SVAS or
WBS leads to the increased proliferation of arterial SMCs. This results in the formation of multilayer thickening
of the tunica media of large arteries and, consequently, in the development of hyperplastic intimal lesions leading
to segmental arterial occlusion.
Introduction
The resilience of vascular walls, skin, ligaments, and
lungs are maintained by elastic fibers in the extracellular
matrix (ECM). These fibers are organized into distinct
structures in different tissues: ropelike fibers in lung,
skin, and ligaments; honeycomblike networks in elastic
cartilage; and concentric lamellae in blood vessels (for
reviews, see Rosenbloom et al. 1993; Pasquali-Ronchetti
and Baccarani-Contri 1997). Ultrastructurally, elastic fi-
bers are complex structures with twomajor components:
an amorphous core of extensively cross-linked elastin
that makes up the bulk (190%) of the fiber, and 10–12-
nm microfibrils composed of several distinct glycopro-
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teins (Vrhovski and Weiss 1998; Debelle and Tamburro
1999). Elastin is a polymer of precursor protein (tro-
poelastin) molecules, which have to be secreted from
fibroblasts, endothelial cells, chondroblasts, or vascular
smooth-muscle cells (SMCs) and then properly assem-
bled on a microfibrillar scaffold in the extracellullar
space and covalently cross-linked by lysyl oxidase (LO)
(Kagan and Trackman 1991). Impaired elastogenesis co-
incides with increased SMCmigration and proliferation,
causing physiological occlusion of the fetal ductus ar-
teriosus (Hinek et al. 1991; Hinek and Rabinovitch
1993). A similar association of deficient deposition of
elastin and increased cell proliferation occurs during the
formation of hyperplastic atherosclerotic plaques, as
well as during intimal thickening in posttransplantation
arteriopathy and during angioplasty-induced arterial
restenosis (MacLeod et al. 1994; Ju and Dixon 1996).
We have previously reported that proper elastogenesis
depends on the presence of 67-kD elastin-binding protein
(EBP) encoded by alternatively spliced mRNA from the
b-galactosidase gene (GLB1) (Hinek et al. 1988, 1993;
Privitera et al. 1998). We have established that the EBP
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Table 1
Characteristics of Subjects
Subject (Age [Sex]) Diagnosis Mutation Source(s) of Samples
9001 (31 years [M]) Normal … Fibroblasts
UF130 (21 years [M]) Normal … Fibroblasts
4184 (3 years [M]) Normal … Fibroblasts
4212 (7 mo [M]) Normal … Fibroblasts
9006 (2 mo [M]) Normal … Aortic SMCs
UF125 (49 years [F]) SVAS 1829GrA Fibroblasts
175902 (3 years [M]) SVAS 1195delG Fibroblasts
2250 (3 years [M]) SVAS 1238delG Fibroblasts, aortic SMCs
11719 (3 years [F]) SVAS t (6;7) Fibroblasts
207092 (6 years [M]) WBS WSCR deletiona Fibroblasts
6367 (2 years [M]) WBS WSCR deletiona Fibroblasts
14073 (6 years [M]) WBS WSCR deletiona Fibroblasts
14966 (3 mo [M]) WBS WSCR deletiona Fibroblasts
1001 (teenage [F]) WBS WSCR deletiona Aortic SMCs
a Determined on the basis of FISH analysis.
acts as a recycling molecular “chaperone” protecting the
highly hydrophobic tropoelastin molecules from intra-
cellular self-aggregation and premature degradation and
facilitates their orderly assembly (Hinek andRabinovitch
1994; Hinek et al. 1995). We also found that the cell-
surface–residing EBP mediates cellular attachment to
elastic fibers and acts as a “true receptor,” which, on
contact with soluble elastin-derived peptides, transduces
intracellular signals facilitating cellular motility and pro-
liferation (Hinek 1994, 1996; Jung et al. 1998, 1999).
Recent studies in our laboratories, based on naturalmod-
els of inherited human connective-tissue diseases, have
shed more light on the pathophysiological association
between impaired elastogenesis and heightened cellular
proliferation.
We have shown that patients with GM-1 gangliosido-
sis who have nonsensemutations inGLB1 (also encoding
the EBP) manifest a primary EBP deficiency and, con-
sequently, an impaired elastogenesis (Hinek et al. 2000b).
We also have demonstrated that intracellular and peri-
cellular accumulation of dermatan sulfate in Hurler dis-
ease (Hinek and Wilson 2000), as well as accumulation
of chondroitin sulfate in Costello syndrome (Hinek et al.
2000a), cause functional inactivation of the EBP, which
results in inadequate deposition of insoluble elastin, de-
spite normal synthesis of tropoelastin and adequate pro-
duction of components of the microfibrillar scaffold (mi-
crofibril-associated proteins and fibrillin). Our studies
also have indicated that, in the latter two diseases, im-
paired deposition of insoluble elastin and accumulation
of small elastin-derived peptides coincide with increased
cell proliferation. Impaired elastogenesis and increased
cell growth more than likely contribute to the develop-
ment of connective-tissue abnormalities, including occlu-
sive arterial lesions, found to be associated with these
disorders.
These results of our previous studies were consistent
with studies of mice with a targeted inactivation of the
elastin gene (Eln). Homozygous null mutants for the
elastin gene, ELN/, develop a progressive arterial
disorder characterized by heightened proliferation of ar-
terial SMCs, leading to thickening of the arterial wall
and narrowing of the lumen and resulting in neonatal
death (Li et al. 1998a, 1998b).
To investigate further whether reduced elastin dep-
osition is directly linked to increased cellular prolifer-
ation, the present study compared elastogenesis and the
proliferation rates of cultured aortic SMCs and skin
fibroblasts from healthy control subjects and from pa-
tients with two diseases—supravalvular aortic stenosis
(SVAS [MIM 185500]) and Williams-Beuren syndrome
(WBS [MIM 194050])—characterized by primary ge-
netic disorders of ELN.
SVAS, an inherited obstructive arterial disease, may
occur either as an isolated condition (Eisenberg et al.
1964) or as part of a complex developmental syndrome,
WBS (Williams et al. 1961; Beuren et al. 1962). Isolated
SVAS is caused by point mutations (Li et al. 1997; Tas-
sabehji et al. 1997; Boeckel et al. 1999; Urba´n et al. 1999,
2000a, 2001; Metcalfe et al. 2000; Dedic et al. 2001),
translocations (Curran et al. 1993; von Dadelszen et al.
2000), and deletions (Ewart et al. 1993, 1994; Olson et
al. 1995; Fryssira et al. 1997) in ELN. Most ELN mu-
tations in SVAS result in premature termination codons,
some of which have also been shown to cause nonsense-
mediated decay (NMD) of mutant mRNA products (Ur-
ba´n et al. 2000a, 2001). In WBS, patients are charac-
terized by a complex developmental phenotype that, in
addition to aortic stenosis, includes specific facial fea-
tures, growth deficiency, developmental delay, mental re-
tardation, a specific neurobehavioral profile, and con-
nective-tissue abnormalities, all caused by a genomic
deletion of 1.6 Mb in chromosome 7. This deletion en-
compasses at least 16 (reviewed by Francke [1999]) and
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potentially as many as 24 (DeSilva et al. 2002) genes,
including ELN.Histologic evaluation of the vascular sys-
tem in patients with either SVAS or WBS indicates that
these syndromes should be considered generalized dis-
eases of the arterial wall, causing segmental narrowing
of the aorta and of the pulmonary, carotid, cerebral, re-
nal, and coronary arteries (O’Connor et al. 1985; Rein
et al. 1993; Kaplan et al. 1995). In children with SVAS,
narrowing of the coronary arteries may lead to myocar-
dial infarcts and sudden death (Conway et al. 1990), and
cerebral artery stenoses may lead to cerebral infarcts and
stroke (Kaplan et al. 1995). In both the syndromic and
the isolated forms, stenotic regions of the aorta are char-
acterized by disorganized lamellar architecture of the tu-
nica media and thickening of the intima, which contains
numerous SMCs and is surrounded by an elastin-poor
ECM (O’Connor et al. 1985). Nonstenotic regions of the
aorta in patients with either SVAS or WBS have a nor-
mal lumen diameter but an abnormally high aortic-wall
diameter, resulting from a two- to threefold increase in
SMC layers surrounded by thinner than normal elastic
lamellae. Thus, we hypothesized that inadequate depo-
sition of insoluble elastin may be pathophysiologically
connected to SMC hyperplasia during development of
vascular thickenings in SVAS and in WBS.
The results presented here indicate a strong correla-
tion between abnormally low levels of elastin deposition
and increased cell-proliferation rate of WBS and SVAS
cells. We also show that the increased proliferation rate
of ELN/ cells can be reversed by addition of ex-
ogenous insoluble elastin.
Patients, Material, and Methods
Patients and Samples
The genotypes and characteristics of the study subjects
are summarized in table 1. Detailed clinical and molec-
ular descriptions of families SVAS-9 (175902) and SVAS-
8 (UF125) and of patient 11719 have been published
elsewhere (Kumar et al. 1993; Urba´n et al. 2000a, 2001;
von Dadelszen et al. 2000). An additional patient with
SVAS, patient 2250, underwent mutational analysis as
part of the present study. Clinical diagnosis of all patients
with SVAS was established by echocardiography. All pa-
tients with WBS who were enrolled in this study also
had SVAS, as determined by echocardiography or car-
diac catheterization. After clinical diagnosis, molecular
diagnosis of patients with WBS was established by FISH
with a probe containing loci ELN, LIMK1, andD7S613
(Vysis), with peripheral-blood lymphocytes used as
samples.
Skin biopsies were taken as 4-mm punch biopsies from
healthy donors or from tissue excised as part of either
cardiac surgery or catheterization from a sun-protected
region (e.g., upper inner arm, chest, or inguinal region).
Biopsy samples were diced and explanted in a-MEM
(modified Eagle’s medium) supplemented with 10% fe-
tal bovine serum (FBS), 25 mM N-2-hydroxyethylpi-
perazine-N-2-ethanesulfonic acid (HEPES), L-glutamine,
and antibiotics. Aortic tissue samples were excised from
a patient with SVAS (patient 2250) and from a patient
with WBS (patient 1001), during surgical correction of
aortic stenosis. Tissue samples were diced, and cells were
isolated by digestion with collagenase and elastase, as
described elsewhere (Oakes et al. 1982). Passage two of
aortic SMCs from a healthy control subject (subject
9006) was purchased from Clonetics.
Material
All chemical-grade reagents were obtained from Sig-
ma. a-MEM, cell-culture media, FBS, and other cell-
culture products were obtained from GIBCO Life Tech-
nologies. Powdered bovine ligamentum nuchae insolu-
ble elastin and a polyclonal antibody to tropoelastin
were purchased from Elastin Products. Monoclonal an-
tibody against smooth-muscle a-actin, polyclonal anti-
body to human von Willebrand factor and secondary
antibodies—fluorescein-conjugated goat anti-rabbit
(GAR-FITC) and fluorescein-conjugated goat anti-mouse
(GAM-FITC)—were purchased from Sigma. Monoclonal
antibody to fibronectin (mAB1940) was from Chemicon,
and polyclonal antibody to LO was a generous gift from
Dr. Katalin Ciszar (University of Hawaii). The DNeasy
Tissue System for DNA assay was from Qiagen. The
BigDye cycle sequencing kit was from Perkin-Elmer. The
superscript preamplification system was from Life Tech-
nologies; the TRI-reagent was from the Molecular Re-
search Center (Cincinnati); and the bromodeoxyuridine
(BrdU) labeling and immunostaining kit was from
Zymed Laboratories. Radiolabeled reagents, [3H]-val-
ine, and [3H]-thymidine were purchased fromAmersham
Canada.
Histopathology
We examined 4-mm-thick histological sections of aorta,
pulmonary artery, and extramural coronary arteries,
which were obtained during autopsy of twomale children
(1 and 2 years old) with SVAS, two patients (1 and 2
years old) with WBS, and two 2-year-old male children
who died of non–vascular-related diseases.All histological
sections were stainedwithmodifiedMovat’s pentachrome
method (Garvey et al. 1986), which shows elastin as
black, glycosaminoglycans as green, collagen as yellow,
smooth muscle as red, and nuclei as dark blue. The dis-
tribution of black-stainedmaterial inMovat’smethod has
been shown to overlap completely with immunodetect-
able elastin (de Chalain et al. 1999).
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Cell Cultures
Cells were maintained in a-MEM supplemented with
20 mM HEPES, 1% L-glutamate, 1% sodium pyruvate,
nonessential amino acids, 1% antibiotics, and 10% FBS
and were routinely passaged by trypsinization. All the
experiments described below were performed by using
SMCs at passages 2–5 and fibroblasts at passages 4–8.
Primary SMC cultures were found to be positive for
indirect immunofluorescent staining with a monoclonal
antibody against smooth-muscle a-actin (A2547; Sigma)
and were found to be negative for a polyclonal antibody
against human von Willebrand factor (F3520; Sigma).
Mutational Analysis
Mutational analysis of patient 2250 was conducted as
described elsewhere (Urba´n et al. 2000a). In brief, a com-
bination of single-strand conformation analysis (SSCA)
and conformation-sensitive gel electrophoresis (CSGE
[Ganguly et al. 1993]) was used tomaximize the efficiency
of mutation detection. Each individual exon of ELN was
amplified with flanking intronic sequences, in a radio-
active PCR. Aliquots of reaction products were subse-
quently taken and analyzed, in a parallel fashion, by SSCA
and CSGE. Exons with mobility shifts were further an-
alyzed, by direct sequence analysis. The nucleotide num-
bering used in the present study reflects the coding region
of ELN, as described elsewhere (Tassabehji et al. 1997).
This region contains all exons, including exons 22 and
26A (Bashir et al. 1989) but not the alternatively spliced
exon 24A (exon 12A in the original nomenclature) (Fazio
et al. 1991).
RNA Expression Studies
Fibroblasts were cultured to confluence at passages
4–8, in Dulbecco’s a-MEM supplemented with 10%
FBS, 25 mM HEPES, L-glutamine, and antibiotics. For
NMD studies, parallel confluent cultures were incubated
for 4 h, with or without 100 mg of cycloheximide (CHX)/
ml, before RNA extraction. RNA was extracted by use
of TRI-reagent. For analysis of allelic expression, 0.5 mg
of total RNA was used to generate first-strand cDNA,
by the superscript preamplification system and random
primers. First-strand cDNA was amplified either by oli-
gonucleotide HEE18.1S (5′-GGG ATC CCA GGT GCT
GCG GTT-3′) (which is complementary to exon 18) or
by oligonucleotides MH1 (5′-CGG AGT TGG AGG
CAT TC-3′) and MH2 (5′-ACC GTA CTT GGC AGC
CTT-3′) (which are complementary to exons 20 and 21,
respectively), resulting in a product of 287 bp or 193
bp, respectively. RT-PCR products were analyzed by di-
rect sequencing using the BigDye cycle sequencing kit.
Alternatively, radioactive PCR products were generated
by end-labeled oligonucleotide MH2 and then were an-
alyzed by SSCA. Steady-state levels of elastin mRNA
were analyzed by RNA blot hybridization using a human
elastin cDNA recombinant H-11 (Olson et al. 1995) as
a probe, as described elsewhere (Urba´n et al. 2000a).
For mRNA stability studies, parallel triplicate cultures
were grown to confluence in six-well plates. Total
mRNA was isolated from untreated cultures and from
cultures treated, for 6, 12, or 24 h, with 60 mM of 5,6-
dichlorobenzimidazole riboside (Zhang et al. 1995), and
samples were analyzed by RNA blot hybridization using
probe H-11.
Immunostaining
Subconfluent 2-d-old cultures of aortic SMCs and fi-
broblasts, from healthy control subjects and frompatients
with either SVAS or WBS, which do not deposit elastic
fibers, as well as 10-d-old confluent cultures of these cells,
which produce abundant ECM, were used. All cultures
were fixed in cold 100% methanol at 20C for 30 min,
were blocked with 1% normal goat serum, and then were
incubated for 1 h, either with 20 mg of anti-S-GAL an-
tibody/ml, which recognizes the elastin-binding domain
of the elastin receptor (Hinek et al. 1993), or with 10 mg
of antibody to LO/ml, an enzyme responsible for cross-
linking of the secreted tropoelastin. The 10-d-old conflu-
ent cultures of normal fibroblasts, SVAS fibroblasts, and
WBS fibroblasts were immunostained for 1 h, with either
20 mg of polyclonal antibody to tropoelastin/ml, which
also detects insoluble extracellular elastin (Prosser et al.
1991), or with 1 mg of monoclonal antibody to fibronec-
tin/ml, as described elsewhere (Hinek and Wilson 2000).
All cultures were then incubated for an additional 1 h,
with the appropriate GAR-FITC or GAM-FITC secon-
dary antibodies. Nuclei were counterstained with propi-
dium iodide. As a control for all the immunostaining,
either preimmune rabbit IgG or normal mouse ascites
fluid was substituted for the primary antibodies. Second-
ary antibody alone was used as an additional control.
Quantitative morphometric analysis of 10-d-old cul-
tures immunostained with antibodies against ECM com-
ponents was performed by use of an Olympus AH-3 mi-
croscope attached to a CCD camera (Optronics) and a
computer-generated video analysis system (Image-Pro
Plus software; Media Cybernetics). Fifty low-power
(#20) fields from three separate cultures derived from
three different patients in each analyzed group (i.e., nor-
mal, SVAS, and WBS ) were analyzed, and the area oc-
cupied by the particular immunodetectable component
was quantified. The abundance of each component was
then expressed as a percentage area of the entire analyzed
field.
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Assay of Insoluble Elastin
In each experiment, either SMCs from a healthy control
subject (subject 9006), from a patient with SVAS (patient
2250), and from a patient withWBS (patient 1001) (table
1) or fibroblasts derived from four patients belonging to
each experimental group (table 1) were plated in 60-mm
culture dishes (100,000 cells/dish) andwere grown to con-
fluence for 48 h. Then, 2 mCi of [3H]-valine was added
to each dish, along with fresh media. Cultures then were
either incubated for the next 2 d or maintained in a time
course as long as 10 d in the presence of radioactive valine
(fresh media were added at days 3 and 6). At each time
point of the course, quadruplicate cultures belonging to
each experimental group were terminated, at days 3, 6,
and 10, and insoluble elastin was assessed. After the re-
moval of the media, cell layers containing insoluble elastin
deposited in ECM were washed in 0.1 M acetic acid and
then were scraped in 0.1 N NaOH, were sedimented by
centrifugation, and, to dissolve all ECM components ex-
cept elastin, were boiled, for 45 min, in 0.5 ml of 0.1 N
NaOH. The resulting pellets containing the insoluble elas-
tin were then dissolved by being boiled in 200 ml of 5.7
N HCl for 1 h, and the aliquots were mixed with scin-
tillation fluid and were counted (Hinek et al. 1993; Hinek
and Rabinovitch 1994). Aliquots taken from each cul-
ture were also used for DNA determination by the
DNeasy Tissue System from Qiagen. Final results reflect-
ing amounts of metabolically labeled insoluble elastin
were expressed as counts per minute per microgram of
DNA.
Assessment of Cell Proliferation
In each experiment, SMCs or fibroblasts were seeded
in six-well dishes, at a density of 50,000 cells/well, in a-
MEM containing 10% FBS. The medium was changed
24 h later, and parallel cultures were maintained for pe-
riods of 1–10 d, as specified in the figure legends. At the
end of each incubation period, the cell proliferation was
studied in each culture, by use of the BrdU labeling and
immunostaining kit, according to the manufacturer’s in-
structions. Cells from individual cultures were also tryp-
sinized and counted in a hemocytometer. Additionally,
assay of total DNA was performed at each end point, by
the DNeasy Tissue System (Rodems et al. 1998). Parallel
sextuplicate cultures incubated as described above were
also exposed to [3H]-thymidine (2 mCi/well) for the last
24 h. These cultures were then washed in PBS and were
treated with cold 5% trichloroacetic acid twice for 10
min at 4C. Then, 0.5 ml of 0.3 N NaOH was added to
all dishes, for 30 min. Subsequently, 200-ml aliquots of
each culture were mixed with scintillation fluid and were
counted.
In a separate series of experiments, the incorporation
of [3H]-thymidine by SMCs or fibroblasts derived from
all listed healthy control subjects and from patients with
either SVAS or WBS was also measured in 3-d-old quad-
ruplicate cultures. All cells were plated at the same initial
density of 50,000 cells/dish and were maintained either
in medium (containing 10% FBS) in the presence or
absence of 1 mg of insoluble elastin/ ml or in medium
that was exposed only to insoluble elastin. This medium,
also containing 10% of FBS, was preincubated, for 1 h,
with 1 mg of insoluble elastin/ml. Elastin was then re-
moved by centrifugation, and the supernatant was added
to the cell cultures. Results from two different experi-
ments were combined and were expressed as the per-
centage of change, compared with the results for un-
treated controls within the same cell type.
Data Analysis
In all biochemical studies, means and SDs were cal-
culated, and statistical analyses were performed by anal-
ysis of variance.
Results
Medial Thickening and Formation of Neointima in
Arteries of Patients with either SVAS or WBS
To illustrate structural changes in SVAS arteries and
in WBS arteries, we compared histologic sections of the
ascending aorta of infants with either isolated SVAS or
isolated WBS versus controls taken from infants who
died of nonvascular causes. Our assessment confirmed
that nonstenotic regions of aorta from patients with ei-
ther SVAS or WBS had thickened tunica media char-
acterized by an increased number of layers of SMCs
surrounded by thinner-than-normal elastic lamellae (fig.
1A and B). Assessment of medial layers of the stenotic
regions in these cases indicated that, in contrast to nor-
mal aortic tunica media composed of parallel elastic la-
mellae separated by single layers of SMCs (fig. 1C), the
lamellar architecture of the tunica media was disorgan-
ized and contained multiple clusters of SMCs separated
by thin, fragmented elastic fibers (fig. 1D). The obstruc-
tive intimal thickening detected in the SVAS aorta and
the WBS aorta (fig. 1E) was formed by numerous SMCs
surrounded by an elastin-poor ECM. Our patients with
either SVAS or WBS who were evaluated also showed
concentric intimal hyperplasia, with a reduction in the
lumen of the main trunk of the pulmonary artery and
in the coronary arteries, characterized by the presence
of scarce, fragmented elastic fibers (data not shown).
Mutational Analysis of SVAS Samples and WBS
Samples—and Functional Haploinsufficiency in SVAS
To be able to work with fibroblasts and SMC samples
of defined genotypes, we analyzed mutations in all pa-
tients included in the present study (table 1). A char-
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Figure 1 A and B, Representative photomicrographs comparing a transverse section of the ascending aorta of a healthy 2-year-old child
(A) and the nonstenotic region of the ascending aorta of 2-year-old patient with WBS (B) (staining is with Movat’s pentachrome; original
magnification #100). Nonstenotic regions of the WBS aorta demonstrate a larger-than-normal aortic-wall diameter, resulting from an increase
in the number of SMC layers surrounded by abnormally thin elastic lamellae. C–E, Higher-power images of sections stained with Movat’s
pentachrome (magnification#400), comparing the tunica media of the aorta of a healthy 2-year-old child (C) and the medial (D) and neointimal
(E) layers of the stenotic region of the aorta of a 2-year-old patient with WBS. In contrast to the normal aortic tunica media composed of
parallel elastic lamellae separated by single layers of SMC, in the stenotic region the lamellar architecture of the tunica media is disorganized
and contains multiple clusters of SMC separated by thin, fragmented elastic fibers (D). The intimal thickening of the WBS aorta is composed
of numerous SMC surrounded by elastin-poor ECM (E).
acteristic microdeletion in chromosomal region 7q11.2
was found by FISH analysis of peripheral blood samples
of all patients with WBS. We used cells from patients
with SVAS and previously analyzed mutations, including
patients 175902 (SVAS-9; Urba´n et al. 2000a), UF125
(Urba´n et al. 2001), and 11719 (von Dadelszen et al.
2000). For two of these patients (patients 175902 and
UF125), we had shown, in previous studies (Urba´n et
al. 2000a, 2001), that the mutations represent function-
ally inactive (null) alleles.
One additional patient with SVAS, who served as a
donor for both skin fibroblasts and aortic SMCs, under-
went a mutational analysis, which identified mutation
1238delG (fig. 2A and B). RT-PCR analysis of the ex-
pression of the mutation both in skin fibroblasts and in
aortic SMCs from this patient indicated that the mutant
allele was not expressed (fig. 2C). The expression of the
mutant mRNA was restored by CHX treatment, indi-
cating that this frameshift mutation results in a premature
termination codon that activates the NMD mechanism.
Similar to mutations 1195delG and 1829GrA, therefore,
mutation 1238delG is a null allele. Consistent with this
finding, we observed reduced elastin mRNA levels both
in aortic SMCs and in fibroblasts from this patient and
from other patients with either SVAS orWBS, when RNA
blot hybridization was used (figs. 2D and 3).
Interestingly, WBS cells showed significantly ( ;P ! .01
t test) lower elastin mRNA levels than did SVAS cells (figs.
2D and 3). In fibroblasts the mean mRNA levels were
61%  4% of normal levels, whereas in the WBS cells
elastin mRNA levels were 14% 14% of normal levels.
To investigate why elastin mRNA levels were reduced
below the expected 50% of normal levels, we studied the
stability of elastin mRNA by treating a healthy control
subject (subject 9001), a patient with SVAS (patient
175902), and a patient with WBS (patient 207092) with
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Figure 2 Identification of a new elastin-gene mutation in patient
2250 from family SVAS-31, and reduced elastin mRNA expression in
SVAS SMCs andWBS SMCs. A, CSGE of ELN exon 20, which detects
a mobility shift in patient 2250 (arrow). Samples from families SVAS-
21 and SVAS-22 are included as negative controls, and a sample from
family SVAS-26 is included as a positive control. B, DNA sequence
analysis of exon 20, which identifies a guanosine deletion at position
1238 (1238delG), which is predicted to result in premature termination
of translation. C, RT-PCR analysis of exon 20 in skin fibroblasts (Fib)
and aortic SMCs (Ao) in patient 2250, which indicates that elastin
mRNA containing mutation 1238delG is degraded by the NMDmech-
anism. Inhibition of NMD by cycloheximide (CHX) restores the ex-
pression of the mutant transcript. Samples from a normal skin-fibro-
blast line (9001) are included as controls. D, RNA blot analysis of
elastin mRNA in aortic SMC from a patient with WBS (1001), a
patient with nonsyndromic SVAS (2250), and a healthy control subject
(9006), which show reduced total elastin mRNA in WBS and SVAS
samples. Note that elastin mRNA abundance is less in WBS than in
SVAS. Ethidium bromide staining of 28S rRNA is included as a control.
Figure 3 Phosphorimager analysis of elastin mRNA abundance
in normal, SVAS, and WBS fibroblasts. RNA samples were analyzed
by blot hybridization using elastin cDNA probe H-11. The intensity
of the hybridization signal (gels “ELN” [inset]) was normalized to the
abundance of 28S rRNA (gels “28S” [inset]) in the corresponding gel
stained with ethidium bromide, and the resulting values are shown,
in the bar graph, in arbitrary units. The order of the samples in the
inset is the same as in that in the bar graph.
the transcription inhibitor DRB (5,6-dichlorobenzimida-
zole riboside), for 0, 6, 12, and 24 h. The half-life of
elastin mRNAwas 13.5 1.25 h in SVAS cells and 13.25
 0.9 h in WBS cells. Thus, there was no significant
difference, in elastin mRNA stability, between SVAS cells
and WBS cells.
To exclude the possibility of somatic mosaicism for
ELN deletions, we conducted FISH analysis on aortic-
cell isolates. Disomy was confirmed in patient 2250 with
SVAS, and monosomy was confirmed in patient 1001
with WBS, with 30 mitoses analyzed in each sample
(data not shown).
Inverse Relationship between Deposition of Insoluble
Elastin and Cellular Proliferation
To analyze elastin deposition in cells with null muta-
tions of ELN, we used morphometric analysis of indirect
immunofluorescent staining and metabolic labeling fol-
lowed by biochemical isolation of insoluble (extracellu-
lar) elastin. These studies indicated that cultured aortic
SMCs obtained from a patient with SVAS and from a
patient with WBS produced ∼30% less and ∼90% less
insoluble elastin, respectively, than did SMCs derived
from healthy subjects (fig. 4A and E). Concomitantly, we
showed a two- to fourfold increase in the proliferation of
SVAS SMCs andWBS SMCs, respectively, comparedwith
those in normal controls, by measuring the incorporation
of [3H]-thymidine (fig. 4F). A corresponding increase of
cell proliferation was observed by following the incor-
poration of BrdU, by use of immunohistochemical stain-
ing (fig. 4D).
Immunofluorescent microscopic studies revealed that,
in cultured SMCs and fibroblasts derived from patients
with either SVAS or WBS, immunodetectable expression
of EBP and LO was similar to that in their counterparts
derived from healthy control individuals (fig. 4B and C).
Morphometric analysis of 10-d-old cultures immuno-
stained with anti-elastin and anti-fibronectin antibodies
revealed that SVAS fibroblasts and WBS fibroblasts pro-
Figure 4 A, Representative photomicrographs of 10-d-old cultures of human aortic SMC immunostained with specific antibodies to elastin
(magnification#100). Nuclei were counterstained with propidium iodide. B and C, Representative higher-power images (magnification#400)
comparing expression of the EBP and LO in 3-d-old cultures of aortic SMC. D, Representative photomicrographs of 10-d-old cultures of human
aortic SMC metabolically labeled with BrdU and immunostained with anti-BrdU antibodies (brown nuclei), demonstrating higher-than-normal
proliferating rates of SVAS cells and of WBS cells (magnification #40). E and F, Results (mean  SD) of quantitative analysis of a typical
experiment using 3-d-long metabolic labeling of quadruplicate cultures with radioactive valine, followed by biochemical isolation of insoluble
elastin, which demonstrates that aortic SMC from patients with SVAS and patients with WBS deposit, respectively, low and very low amounts
of insoluble elastin (E), and of measurements of [3H]-thymidine incorporation into the parallel quadruplicate cultures, which indicate that
abnormally low levels of insoluble elastin are associated with an inversely proportional increase in the proliferation rate of SMC in patients
with SVAS and patients with WBS (F) (* [ ]).P ! .001
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Figure 5 Results (mean SD) of quantitative assay of insoluble
elastin (metabolically labeled with [3H]-valine) deposited in 3-d-old
cultures of human fibroblasts (A) and assessment of cellular prolif-
eration rate in parallel cultures, measured by incorporation of [3H]-
thymidine for the last 24 h (B). Fibroblasts from all four patients with
SVAS deposited consistently lower amounts of insoluble elastin than
did those from four healthy control subjects. Fibroblasts from all four
patients with WBS deposited even lower amounts of insoluble elastin
than did those from patients with isolated SVAS. These abnormally
low levels are associated with an inversely proportional increase in
proliferation rates. Combined results from three separate experiments,
with quadruplicate cultures of fibroblasts derived from each patient
(initially plated 100,000 cells /dish), indicate that differences between
experimental groups, normal versus SVAS, normal versus WBS (*
[ ]), and SVAS versus WBS (** [ ]) are statistically sig-P ! .002 P ! .05
nificant. Differences between cultures derived from different patients
within each experimental groups are not statistically significant.
duced 48% and 87% less insoluble elastin, respectively,
than did fibroblasts derived from healthy control subjects.
Interestingly, this low deposition of extracellular elastin
by SVAS fibroblasts and WBS fibroblasts coincided with,
respectively, 36% and 84% increases in production of
fibronectin, compared with levels observed in cultures of
normal fibroblasts. Similar levels of increase in deposition
of fibronectin, compared with levels observed in cultures
of normal SMCs, were visible also in SVAS aortic SMCs
and in WBS aortic SMCs, which showed 42% and 88%
increases, respectively.
To further establish that the observed inverse rela-
tionship between elastin deposition and cell proliferation
is not due merely to random interindividual variations,
we studied groups of normal fibroblasts, SVAS fibro-
blasts, and WBS fibroblasts, from four individuals in
each group. Elastin deposition as assessed by metabolic
labeling and by biochemical isolation of elastin was re-
duced in SVAS fibroblast cultures and in WBS fibroblast
cultures, to ∼50% and ∼15% of normal values, respec-
tively (fig. 5A). By measuring [3H]-thymidine incorpo-
ration in the same group of SVAS fibroblasts and in the
same group of WBS fibroblasts, we demonstrated re-
spective twofold and fourfold increases in proliferation
rate, compared with the levels in normal cells (fig. 5B).
To investigate the kinetics of elastin deposition and
cell proliferation, we studied these variables in 1–10-d-
old cultures of selected fibroblast cell lines, which were
densely plated (100,000 cells/dish) to reach an imme-
diate confluence. Throughout the entire study period,
normal cells consistently deposited the most elastin,
SVAS cells deposited intermediate amounts, and WBS
cells deposited the least (fig. 6A). Assessment of cell pro-
liferation, by measurement of DNA content and by cell
counting, revealed that both WBS fibroblasts and SVAS
fibroblasts showed a consistent increase in proliferation
rates, compared with that in normal controls (fig. 6B).
Moreover, proliferation rates of these confluent fibro-
blasts, which quickly started production of their ECM,
were always inversely proportional to amounts of in-
soluble elastin deposited during the entire 10-d-long time
course. Interestingly, results of an additional experiment
showed that cells (initially plated 10,000 cells /dish) that
remained subconfluent in 2-d-old cultures and that did
not deposit abundant ECM did not demonstrate any
significant differences, in proliferation rates, between
normal fibroblasts, SVAS fibroblasts, and WBS fibro-
blasts (data not shown).
Since our experiments clearly demonstrate that both
SVAS cells with a reduced rate of elastin synthesis and
WBS cells with a reduced rate of elastin synthesis show
increased proliferation rates (figs. 4–7), we attempted to
reverse this hyperproliferative phenotype, by adding ex-
ogenous insoluble elastin to cultures of SMCs and fi-
broblasts. Our results indicate that supplementation with
insoluble elastin significantly lowers the proliferationrates
of all tested cell types (fig. 7). Meaningfully, a similar
decrease in proliferation rates was observed also in cul-
tures of cells maintained in media that were preincubated
with insoluble elastin (fig. 7).
Discussion
Results of our present study, which uses an experimental
model involving cells from patients with either SVAS or
WBS who exhibit the primary genetic defects of ELN,
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Figure 6 Results of a typical experiment when quantitative assays of metabolically labeled insoluble elastin (A) and assessments of cellular
proliferation (B), measured by total DNA assay and cell counting, were performed in the time course. Results consistently showed that the
abnormally high proliferation rate of cultured SVAS fibroblasts and of WBS fibroblasts is inversely proportional to their deposition of insoluble
elastin during the entire 10-d culture period. At each time point, quadruplicate cultures of fibroblasts derived from each patient (initially plated
100,000 cells/dish) were assessed. Statistical evaluation showed that at 3, 6, and 10 d, the time-point differences between normal versus SVAS,
normal versus WBS, and SVAS versus WBS were statistically significant.
show for the first time a direct causative relationship
between reduced elastin deposition and increased pro-
liferation of human cells. Results of our in vitro studies
with aortic SMCs and skin fibroblasts clearly show that
an inverse relationship between deposition of insoluble
elastin and heightened cellular proliferation is an im-
portant feature of both the SVAS phenotype and the
WBS phenotype.
Functional Haploinsufficiency in SVAS
ELN mutations have been shown to cause SVAS (Cur-
ran et al. 1993; Ewart et al. 1994; Olson et al. 1995;
Fryssira et al. 1997; Li et al. 1997; Tassabehji et al. 1997;
Boeckel et al. 1999; Urba´n et al. 1999, 2000a, 2001;
Metcalfe et al. 2000; von Dadelszen et al. 2000; Dedic et
al. 2001). However, few studies have investigated the
mechanism by which these mutations cause disease. We
have recently shown that premature termination muta-
tions in ELN activate an NMDmechanism that degrades
mutant mRNA and renders the mutations as functionally
inactive, null alleles (Urba´n et al. 2000a, 2001). We have
further shown that these null mutations result in reduced
synthesis and secretion of tropoelastin. The studies pre-
sented here extend our previous results in several ways.
We have shown nonsense mediated degradation (i.e.,
NMD) of the mutant mRNA in a new SVAS allele and
have used it to demonstrate for the first time that NMD
of mutant elastin mRNA is active not only in skin fibro-
blasts but also in aortic SMCs, the most relevant cell type
for the pathogenesis of SVAS. Furthermore, our current
data demonstrate that SVAS alleles not only cause reduced
ELN expression at the mRNA and protein levels but also
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Figure 7 Results of typical experiment comparing [3H]-thymi-
dine incorporation into quadruplicate cultures of aortic SMC (A) and
skin fibroblasts (B), derived from healthy control subjects, patients
with SVAS, and patients with WBS, which were maintained for 3 d
in the presence or absence of either 1mg of exogenous insoluble elastin/
ml or media that were preincubated for only 1 h with the 1 mg of
exogenous insoluble elastin/ml. Statistical evaluations indicate that
higher-than-normal proliferation of SMC and fibroblasts derived from
patients with SVAS and patients with WBS was significantly reduced
either in cultures treated with exogenous insoluble elastin or when
maintained in media preincubated with insoluble elastin (* [ ]).P ! .002
Both treatments also decreased the proliferation rate of normal fibro-
blasts (** [ ]).P ! .05
result in reduced deposition of elastic fibers. The latter is
not a trivial finding, since elastic-fiber deposition requires
the interaction and assembly of multiple cellular and ex-
tracellular proteins, including EBP (Hinek and Rabinov-
itch 1994; Hinek et al. 1995), fibrillin-1 and fibrillin-2
(Trask et al. 2000), microfibril-associated glycoproteins
(Brown-Augsburger et al. 1996), and fibulin -5 (Naka-
mura et al. 2002). Thus, our findings indicate that tro-
poelastin synthesis and secretion is a rate-limiting step in
elastic-fiber assembly.
Elastin Biosynthesis in WBS
WBS is caused by segmental monosomy of a 1.6-Mb
region in 7q11.2. Since the WBS critical region (WSCR)
includes ELN, the pathomechanism of vascular disease
in WBS is clearly elastin haploinsufficiency. One concern
with analysis of the effects of elastin haploinsufficiency
in WBS is the potential influence that the deletion of
other WSCR genes has on the phenotypic expression.
Clinical studies to compare the natural history of syn-
dromic and nonsyndromic SVAS are currently unavail-
able. However, early studies on the pathology and his-
tology of vascular lesions suggested that syndromic and
nonsyndromic elastin arteriopathy have similar char-
acteristics (O’Connor et al. 1985). Our studies, too, sug-
gest that vascular lesions in nonsyndromic and syn-
dromic forms of SVAS are very similar.
In contrast, our in vitro studies demonstrate a repro-
ducible difference, in steady-state levels of elastinmRNA
and in elastin deposition, between isolated SVAS SMCs
and isolated WBS SMCs. SMCs and dermal fibroblasts
from all patients with WBS whom we studied had sig-
nificantly reduced elastin mRNA levels and deposited
less elastin than did the same types of cells from patients
with nonsyndromic SVAS. We initially speculated that
such a significant difference in net deposition was related
to the possible loss of the remaining copy of ELN by
WBS cells. FISH analysis of SMCs isolated from the
stenotic region of the aorta of one patient with WBS,
patient 1001, did not confirm such a two-hit hypothesis.
In addition to gene copy number, other determinants
of mRNA steady-state levels are the rates of transcrip-
tion, the transfer of mRNA from the nucleus to the cy-
toplasm, and the rate of mRNA degradation. We have
demonstrated that elastin mRNA stability is the same in
SVAS cells and in WBS cells and thus we assume that,
as a result of haploinsufficiency of one or more deleted
genes within the WSCR, WBS cells have either reduced
transcription of ELN or reduced nuclear transport of
elastin mRNA. Indeed, among the 16 genes deleted in
WBS, there are 4—GTF2IRD1, WBSCR9, WBSCR14,
and TBL2—that encode putative transcription factors.
We speculate that, if one or more of these putative nu-
clear factors up-regulate ELN transcription, haploin-
sufficiency of these genes may result in the markedly
reduced expression of ELN in WBS cells that we have
observed. Independent of the exact mechanism of re-
duced ELN expression in WBS, our results indicate the
existence of a significant gene interaction between ELN
and other genes within the WSCR. This and other gene-
interaction effects may contribute to difficulties associ-
ated with elucidation of the contribution that individual
deleted genes make to the WBS phenotype.
Quantitative and qualitative studies on elastic-fiber
morphology in WBS skin (Dridi et al. 1999, Urba´n et al.
2000b) have indicated that reduced dermal elastin depo-
sition is associated with a soft, smooth, “velvety” skin
phenotype. Similar studies on the skin of patients with
isolated SVAS have indicated normal skin histology (Dridi
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et al. 1999; Z.U., unpublished results). Our in vitro data
demonstrating reduced elastin deposition by WBS cells,
compared with that in isolated SVAS cells, support these
earlier data. Thus, elastin-biosynthesis differences be-
tween syndromic and nonsyndromic forms of SVAS may
exist in vivo. However, currently available data are in-
sufficient to test whether such phenotypic differences exist
between the vascular characteristics of patients with iso-
lated SVAS and those of patients WBS.
Elastin and Cell Proliferation
The chemotactic, chemokinetic, and proliferative ef-
fects of proteolytic degradation products of elastin have
been well established (Senior et al. 1980; Kamoun et al.
1995;Wachi et al. 1995; Jung et al. 1998, 1999); however,
until recently, the function of insoluble elastin was
thought to be limited to the conferring of resilience to
tissues. The vascular phenotype of elastin deficiency, how-
ever, is not suggestive of mechanical failure. Previous stud-
ies (O’Connor et al. 1985; Li et al. 1998b) and the results
of the present study indicate that elastin arteriopathy in
SVAS is characterized by a uniform wall thickening with
preserved lamellar structure but an increased number of
lamellae. In addition, the segmental obstructive disease
found in patients with SVAS is characterized by disrupted
lamellae, clumping of SMCs, and an elastin-poor ECM.
Segmental stenoses of arteries in SVAS are preferentially
localized to areas subject to the highest hemodynamic
stress, such as the sinotubular junction and the ascending
region of the aorta and the bifurcation of major arteries.
Our results from in vitro experiments provide strong
evidence that a primary deficiency in deposition of in-
soluble elastin in patients with either SVAS or WBS may
be responsible for increased cell proliferation in vivo.
The proportional inverse relationship between elastin
deposition and cell-proliferation rate became apparent
in all confluent cultures of SMCs and fibroblasts derived
from different patients as soon as cells started to produce
ECM. Interestingly, we did not detect any significant
differences in proliferation rate in 48-h-old subconflu-
ent cultures of normal cells, SVAS cells, and WBS cells,
which do not contact each other and which do not de-
posit elastin. These results suggest that reduced elastin
deposition may contribute substantially to the height-
ened proliferation of arterial SMCs in vivo, independent
of hemodynamic stress–related mitogenic signals (Iwa-
saki et al. 2000). Moreover, our finding that the addition
of exogenous insoluble elastin was able to normalize the
proliferation rate of cultured SVAS cells and of cultured
WBS cells suggests that the proper accumulation of ex-
tracellular elastin may be a negative regulator of cellular
proliferation. The results that we have presented are con-
sistent with both (1) the findings by Li et al. (1998a,
1998b), who reported development of severe obstructive
vascular disease leading to perinatal lethality of homo-
zygous Eln/mutant mice and (2) our previous report
(Hinek and Wilson 2000) on impaired elastogenesis co-
inciding with the heightened proliferation of cells derived
from patients with Hurler disease, who often develop
occlusive arterial lesions similar to those in SVAS.
Potential Mechanisms for the Antiproliferative Effect of
Elastin
The present study did not directly address the molecu-
lar mechanism by which insoluble elastin regulates cell
proliferation. However, on the basis of the results of our
experiments testing the effects of exogenous insoluble
elastin, one can speculate that interactions between cells
and elastin may either initiate antimitogenic signals or
block the mitogenic signals transduced by the common
growth factors present in the FBS-containing medium.
The cell-proliferation decrease caused by insoluble elastin
likely results from several overlapping mechanisms. First,
physical contact between large particles of insoluble elas-
tin and the cell surface may cause both aggregation of
EBP molecules and masking of adjacent growth-factor
receptors that normally transduce mitogenic signals in-
duced by serum-derived growth factors. This notion is
consistent with our previous findings that cell-surfaceEBP
can mask the adjacent interleukin type I receptors inter-
acting with IL-1B and, thereby, can decrease the cellular
response to this cytokine (Hinek et al. 1996). Second,
large hydrophobic particles of exogenous insoluble elastin
may attract soluble tropoelastin-derived peptides present
in the conditioned media and cause their precipitation
(coacervation). Such a depletion of soluble fragments of
tropoelastin, a factor known to generate signals facilitat-
ing proliferation in many cell types, including vascular
SMCs, skin fibroblasts, and astrocytomas (Kamoun et al.
1995; Wachi et al. 1995; Jung et al. 1998, 1999), may
indirectly down-regulate cellular proliferation.Moreover,
insoluble elastin deposited in arterial tunica media may
sequestrate the EBPmolecules from the surface of adjacent
cells (Hinek and Rabinovitch 1994), thereby reducing the
likelihood ofmitogenic response to soluble elastin-derived
peptides. Results of experiments showing that all tested
cell types reduced their proliferation rates when main-
tained in media (containing FBS) that were preincubated
with insoluble elastin strongly suggest that this exogenous
compound sequestrated certain growth factors from the
FBS-containing media.
Regardless of the exact molecular mechanism of the
antiproliferative effect of elastin, our results provide new
insight into the pathomechanism of arterial occlusive dis-
ease in patients with either SVAS or WBS, linking in-
creased cell proliferation to impaired elastogenesis. We
suggest that initial impaired deposition of insoluble elas-
tin, caused by haploinsufficiency of ELN, contributes to
increased proliferation of fetal SMCs. This, in turn, results
in thick aortic tunica media marked by an increased num-
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ber of cell layers. The inability of the nonresilient ECM
to absorb strong physical forces created by the increase
in blood pressure in the ascending aorta and by a tur-
bulent blood flow in bifurcations of the major arteries
may lead to further transduction of stress-related mito-
genic signals that contribute to persistent proliferationand
migration of arterial SMCs, causing, during the postnatal
period, arterial stenoses in patients with either SVAS or
WBS. The data presented in the present study also en-
courage further studies aimed at the development of ther-
apeutic strategies that seek to identify enhanced elastin
deposition that might be beneficial not only for patients
with either SVAS or WBS but also for those with both
atherosclerosis and angioplasty-induced arterial stenoses.
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